SUNNYVALE, CA --(Marketwired - January 26, 2016) - Viveve Medical, Inc. ("Viveve") (
"We are thrilled about our expanded partnership with DMT, which also has distribution rights in Taiwan. We believe it will solidify Viveve as the premier product for the treatment of vaginal laxity in the Asia Pacific region and greatly increase the availability of the Viveve Treatment," said Patricia Scheller, the Chief Executive Officer of Viveve. "The clinically demonstrated safety and efficacy profile of this painless procedure makes the Viveve Treatment the best alternative for treating a condition that can profoundly impact a woman's sexual satisfaction and quality of life."
"Our commitment is to provide physicians and medical professionals with high quality, clinically-proven products that fulfill their needs and deliver exceptional marketing, training and maintenance service," said Justin Jen, Vice President of DMT. "We offer only what we believe are the best technologies -- those that provide us with evidence of safety and optimal results. The Viveve System is in precise alignment with our goal of bringing innovative technologies to our physicians and their patients. Now women who have this very common and frustrating condition will have access to a safe and proven procedure that is aimed at improving vaginal laxity and restoring sexual satisfaction."
Viveve now has 16 exclusive distribution partnerships covering 50 countries throughout the world with regulatory clearance in 22 of those countries:
| GEOGRAPHIC REGION | DISTRIBUTION COVERAGE | REGULATORY CLEARANCE |
| North America | 1 | 1 |
| Europe | 28 | 18 |
| Asia Pacific | 11 | 3 |
| Middle East | 10 | - |
| TOTAL | 50 | 22 |
About Viveve
Viveve, Inc., the operating subsidiary of Viveve Medical, Inc., is a women's health company passionately committed to advancing new solutions to improve women's overall well-being and quality of life. The company's lead product, the globally patented Viveve System, is a non-surgical, non-ablative medical device that remodels collagen and restores tissue with only one treatment session. The Viveve System treats the condition of vaginal laxity, which is the result of the over-stretching of tissue during childbirth that can result in a decrease in physical sensation and sexual satisfaction. Physician surveys indicate that vaginal laxity is the number one post-delivery physical change for women, being more prevalent than weight gain, urinary incontinence or stretch marks. The Viveve Treatment uses patented, reverse-thermal gradient radiofrequency technology to tighten vaginal tissue in one 30-minute out-patient treatment in a physician's office. The Viveve System has received regulatory approval in Europe, Canada and Hong Kong and is available through physician import license in Japan. It is currently not available for sale in the U.S. For more information, please visit Viveve's website at www.viveve.com .
Safe Harbor Statement
All statements in this press release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this press release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of our control, which could cause actual results to materially differ from such statements. Such risks, uncertainties and other factors include, but are not limited to, the fluctuation of global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are to be detailed in our periodic and current reports available for review at www.sec.gov . Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Viveve is a registered trademark of Viveve, Inc.
Contact: Amato and Partners, LLC Investor Relations Counsel 90 Park Avenue. 17th Floor New York, NY 10016 212.430.0360 admin@amatoandpartners.com
